Dean Petkanas is a corporate finance and executive management professional with over 25 years of investment banking and capital markets experience.

In 2010 Mr. Petkanas co-founded Neuropathix, Inc. and for the past 9 years was principally responsible for the creation and execution of the Company's business model, including the licensing of US Patent #6630507 from the National Institutes of Health for disease indications Hepatic Encephalopathy (HE) and Chronic Traumatic Encephalopathy (CTE). In 2013, he was responsible for securing Series A financing for Neuropathix, Inc.

Mr. Petkanas is a co-inventor of US Patent #9611213 "Novel Functionalized 1,3 Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy"

Mr. Petkanas' background in pharmaceutical extends to his work as investment banker and subsequently V.P. of Business Development for Xechem International, Inc. where he was principally responsible for Xechem's IPO and EXIM Bank rounds of financing. Mr. Petkanas was involved with Xechem from 1992 to 2007. While at Xechem, he was involved in the financing of Xechem's lead target drug candidate (generic paclitaxel) and later on from 2003 to 2007, was the the lead petitioner for Xechem International in steering their federal anti-trust lawsuit against Bristol-Myers-Squibb for their illegal monopoly of the drug market for the anti-cancer drug, Taxol™. Mr. Petkanas also was an integral part of the development team that named, trademarked and commercialized Hemoxin (Nicosan), a phyto-pharmaceutical compound for the treatment of Sickle Cell disease.

Dr. Kinney is a medicinal chemist and entrepreneur with greater than 25 years of experience in large pharmaceutical (Wyeth, Johnson & Johnson), biotechnology (Magainin), and non-profit (Blumberg Institute) research and development. He has demonstrated expertise in drug design; synthesis; lead optimization of peptides, small molecules, and natural products; and is inventor of three molecules that advanced to human clinical trials - Perzinfotel (CNS disorders and pain), Squalamine (oncology and AMD), and Trodusquemine (obesity).

Currently, Dr. Kinney is Director of the Natural Product Discovery Institute and Chief Scientific Officer at Neuropathix, Inc. His scientific contributions include more than 70 publications and presentations; and inventorship on 38 issued U.S. patents.

Dr. Kinney is a co-inventor of Neuropathix's recent US Patent #9611213 "Novel Functionalized 1,3 Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy."

Thoma Kikis is an entrepreneur, media and entertainment executive for over 17 years. For the past 8 years Mr. Kikis has been building Neuropathix, Inc. with the CEO and instrumental in the company's branding and communications.

Prior to co-founding Neuropathix, Mr. Kikis executive produced the comedy film It's a Disaster, starring Julia Stiles, David Cross and America Ferrera and co-produced the award winning film Alps by the innovative Oscar™ nominated director Yorgos Lanthimos. He was a co-founder and Executive Vice President of Ovie Entertainment. He previously produced Darkon, a real-life role play documentary about fictional action characters similar to a real life game of Dungeon's and Dragons. Darkon was purchased for remake by Brad Pitt's Plan B and Paramount Pictures and the documentary was distributed by IFC.

Previously he has also worked with Viacom, MTV Interactive, redesigned MTV.com, The Alexander S. Onassis Public Benefit Foundation, Empire Blue Cross/Blue Shield, Icon Medialab, Teachers College, Columbia University, and TCI/Teachers College Innovations among others.

Mr. Kikis was compelled by his father (who suffered with Hepatic Encephalopathy) and cousin Dr. Steven Kazianis PhD, (who suffered and died of Brain Cancer) to find treatments for neurodegenerative related diseases and has made it his life's goal in finding treatments for diseases that effect the brain.

Mr. Kikis hold a Bachelor of Science in Communications Management from New York University.

Mr. Corrao was formerly a founder and CFO of Strikeforce Technologies, Inc., a publicly traded software development and services company specializing in the development of a suite of integrated computer network security products. In addition to the ten years of his service at Strikeforce, Mr. Corrao has spent numerous years in the public accounting arena specializing in certified auditing, SEC accounting, corporate taxation and financial planning. Mr. Corrao's background also includes numerous years on Wall Street with Merrill Lynch, Spear Leeds & Kellogg and Greenfield Arbitrage Partners. While on Wall Street Mr. Corrao was involved in several IPO's and has been a guiding influence in several start up companies. Prior to joining StrikeForce, he was the Director of Sales at Applied Digital Solutions from December 2000 through December 2001. Mr. Corrao was the Vice President of Sales at Advanced Communications Sciences from March 1997 though December 2000. Mr. Corrao has a B.S. from CUNY.